Comparison between metamizole and triptans for migraine treatment: a systematic review and network meta-analysis
DOI:
https://doi.org/10.48208/HeadacheMed.2021.32Keywords:
metamizole, triptans, migraine, headache, tension-type headache, dipyroneAbstract
Objective
The aim of this systematic review was to evaluate the efficacy of metamizole and triptans for the treatment of migraine.
Methods
Randomized controlled trials including people who received metamizole or triptan by multiple routes of administration and at all doses as treatment compared to subjects who received another treatment or placebo were included in the systematic review. The primary outcomes were freedom from pain at 2 hours; pain relief at 2 hours; sustained headache response at 24 hours; sustained freedom from pain at 24 hours. The statistical analysis of all interventions of interest were based on random effect models compared through a network meta-analysis. Results
209 studies meeting the inclusion and exclusion criteria were analyzed. Of these, 130 had data that could be analyzed statistically. Only 3.0% provided enough information and were judged to have a low overall risk of bias for all categories evaluated; approximately 50% of the studies presented a low risk of selection bias. More than 75% of the studies presented a low risk of performance bias, and around 75% showed a low risk of detection and attrition bias.
Conclusion
There is no evidence of a difference between dipyrone and any triptan for pain freedom after 2 hours of medication. Our study suggests that metamizole may be equally effective as triptans in acute migraine treatment.
Downloads
References
Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration - PubMed. Neurology. 1994 Jun;S24-39.
Rasmussen BK. Epidemiology of headache. Cephalalgia. 1995;15(1):44–67. DOI: https://doi.org/10.1046/j.1468-2982.1995.1501045.x
The International Classification Of Headache Disorders 2 nd Edition Headache Classification Subcommittee of the International Headache Society.
Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018 May 1;58:4–16. DOI: https://doi.org/10.1111/head.13300
Gil-Gouveia R, Martins IP. Cognition and Cognitive Impairment in Migraine. Vol. 23, Current Pain and Headache Reports. Current Medicine Group LLC 1; 2019. DOI: https://doi.org/10.1007/s11916-019-0824-7
Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache - PubMed. Can Headache Soc . 2013;40((5 Suppl 3)):S1–80. DOI: https://doi.org/10.1017/S0317167100017819
Bigal ME, Bordini CA, Speciali JG. Headache treatment in an emergency room of the city of Ribeirão Preto, Brazil. Arq Neuropsiquiatr. 1999;57(3 B):813–9. DOI: https://doi.org/10.1590/S0004-282X1999000500013
Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: A randomized, double blind, placebo controlled study. Headache. 2002 Oct;42(9):862–71. DOI: https://doi.org/10.1046/j.1526-4610.2002.02204.x
González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Vol. 14, Expert Opinion on Drug Metabolism and Toxicology. Taylor and Francis Ltd; 2018. p. 25–41. DOI: https://doi.org/10.1080/17425255.2018.1416097
Johnston MM, Rapoport AM. Triptans for the management of migraine. Vol. 70, Drugs. Drugs; 2010. p. 1505–18. DOI: https://doi.org/10.2165/11537990-000000000-00000
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Humana y Diet. 2016;20(2):148–60.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. Vol. 349, BMJ (Online). BMJ Publishing Group; 2015. DOI: https://doi.org/10.1136/bmj.g7647
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med. 2015 Jun 2;162(11):777–84. DOI: https://doi.org/10.7326/M14-2385
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. [Internet]. 2011 [cited 2020 Aug 20]. Available from: www.cochrane-handbook.%0Aorg
ICHD-3 The International Classification of Headache Disorders 3rd edition [Internet]. [cited 2020 Sep 25]. Available from: https://ichd-3.org/
Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. National Institute for Health and Care Excellence (NICE); 2014.
Simmonds MC, Higgins JPT. A general framework for the use of logistic regression models in meta-analysis. Stat Methods Med Res. 2016 Dec 1;25(6):2858–77. DOI: https://doi.org/10.1177/0962280214534409
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997 Sep 13;315(7109):629–34. DOI: https://doi.org/10.1136/bmj.315.7109.629
Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics. 1994 Dec;50(4):1088. DOI: https://doi.org/10.2307/2533446
Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA J Am Med Assoc. 2007 Apr 4;297(13):1443–54. DOI: https://doi.org/10.1001/jama.297.13.1443
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265(21):2831–5. DOI: https://doi.org/10.1001/jama.265.21.2831
Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pr. 2004;58(10):913–9. DOI: https://doi.org/10.1111/j.1368-5031.2004.00295.x
Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27(5):414–21. DOI: https://doi.org/10.1111/j.1468-2982.2007.01313.x
Mushet GR, Cady RK, Baker CC, Clements B, Gutterman DL, Davis R. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clin Ther. 1996;18(4):687–99. DOI: https://doi.org/10.1016/S0149-2918(96)80219-0
Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology. 1997;49(5):1225–30. DOI: https://doi.org/10.1212/WNL.49.5.1225
Ryan R, Géraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42 Suppl 2:S84-92. DOI: https://doi.org/10.1046/j.1526-4610.42.s2.6.x
Sheftell FD, Dahlöf CGH, Brandes JL, Agosti R, Jones MW, Barrett PS. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther. 2005;27(4):407–17. DOI: https://doi.org/10.1016/j.clinthera.2005.04.003
Winner P, Mannix LK, Putnam DG, McNeal S, Kwong J, O'Quinn S, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78(10):1214–22. DOI: https://doi.org/10.4065/78.10.1214
Winner P, Adelman J, Aurora S, Lener ME, Ames M. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clin Ther. 2006;28(10):1582–91. DOI: https://doi.org/10.1016/j.clinthera.2006.10.011
Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24(11):947–54. DOI: https://doi.org/10.1111/j.1468-2982.2004.00783.x
Klapper JA, O’Connor S. Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. Cephalalgia. 2000 Jul;20(6):585–7. DOI: https://doi.org/10.1046/j.1468-2982.2000.00079.x
Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, et al. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered<sup>®</sup> Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan. Headache. 2017;57(6):862–76. DOI: https://doi.org/10.1111/head.13105
Stronks DL, Tulen JHM, Bussmann HBJ, Mulder LJMM, Passchier J. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. Headache. 2003;43(8):845–52. DOI: https://doi.org/10.1046/j.1526-4610.2003.03162.x
Tullo V, Valguarnera F, Barbanti P, Cortelli P, Sette G, Allais G, et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia. 2014;34(6):434–45. DOI: https://doi.org/10.1177/0333102413515342
Tietjen GE, Athanas K, Utley C, Herial NA, Khuder SA. The combination of naratriptan and prochlorperazine in migraine treatment. Headache. 2005;45(6):751–3. DOI: https://doi.org/10.1111/j.1526-4610.2005.05143_1.x
Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache. 2008;48(6):921–30. DOI: https://doi.org/10.1111/j.1526-4610.2007.01053.x
Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48(9):1286–93. DOI: https://doi.org/10.1111/j.1526-4610.2008.01092.x
Bigal ME, Bordini CA, Speciali JG. Intravenous dipyrone for the acute treatment of episodic tension-type headache. A randomized, placebo-controlled, double-blind study. Braz j med biol res. 2002;35(10):1139–45. DOI: https://doi.org/10.1590/S0100-879X2002001000005
Fernandes Filho SMM, Costa MS, Fernandes MT, Foerster MV. Comparação de dipirona intravenosa com metoclopramida intravenosa no tratamento de crise aguda de enxaqueca: ensaio clínico randomizado. TT - [Comparison of intravenous dipyrone to intravenous metoclopramide in the treatment of acute crisis of migraine: . Arq Neuropsiquiatr. 2006;64(4):1005–8. DOI: https://doi.org/10.1590/S0004-282X2006000600023
Krymchantowski AV, Carneiro H, Barbosa J, Jevoux C. Lysine clonixinate versus dipyrone (metamizole) for the acute treatment of severe migraine attacks: a single-blind, randomized study TT - Clonixinato de lisina versus dipirona (metamizol) para o tratamento agudo de uma crise intensa de enxaqueca: estudo . Arq neuropsiquiatr. 2008;66(2a):216–20. DOI: https://doi.org/10.1590/S0004-282X2008000200015
Martínez-Martín P, Raffaelli E, Titus F, Despuig J, Fragoso YD, Díez-Tejedor E, et al. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia. 2001;21(5):604–10. DOI: https://doi.org/10.1046/j.1468-2982.2001.00216.x
Tulunay FC, Ergün H, Gülmez SE, Ozbenli T, Ozmenoglu M, Boz C, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. Funct Neurol. 2004;19(3):197–202.
Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology. 2004;62(6):883–7. DOI: https://doi.org/10.1212/01.WNL.0000115105.05966.A7
Ahonen K, Hämäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006;67(7):1135–40. DOI: https://doi.org/10.1212/01.wnl.0000238179.79888.44
Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46(2):212–22. DOI: https://doi.org/10.1111/j.1526-4610.2006.00339.x
Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache. 2007;47(4):511–8. DOI: https://doi.org/10.1111/j.1526-4610.2007.00755.x
Winner P, Farkas V, Stillová H, Woodruff B, Liss C, Lillieborg S, et al. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ). Headache. 2016;56(7):1107–19. DOI: https://doi.org/10.1111/head.12859
Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006;67(3):497–9. DOI: https://doi.org/10.1212/01.wnl.0000231138.18629.d5
Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia. 2014;34(5):365–75. DOI: https://doi.org/10.1177/0333102413510213
Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology. 1997;48(4):1100–3. DOI: https://doi.org/10.1212/WNL.48.4.1100
Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32(10):750–65. DOI: https://doi.org/10.1177/0333102412451358
Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008;48(9):1326–36. DOI: https://doi.org/10.1111/j.1526-4610.2008.01138.x
Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache. 2004;44(9):891–9. DOI: https://doi.org/10.1111/j.1526-4610.2004.04171.x
Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989–97. DOI: https://doi.org/10.1542/peds.106.5.989
Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42(1):49–55. DOI: https://doi.org/10.1046/j.1526-4610.2002.02013.x
Ahrens SP, Farmer M V, Williams DL, Willoughby E, Jiang K, Block GA, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999;19(5):525–30. DOI: https://doi.org/10.1046/j.1468-2982.1999.019005525.x
Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995;25(4):464–9. DOI: https://doi.org/10.1016/S0196-0644(95)70259-8
Allais G, Acuto G, Benedetto C, D'Andrea G, Grazzi L, Manzoni GC, et al. Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci. 2010;31 Suppl 1:S115-9. DOI: https://doi.org/10.1007/s10072-010-0302-9
Allais G, Bussone G, D'Andrea G, Moschiano F, d'Onofrio F, Valguarnera F, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011;31(2):144–51. DOI: https://doi.org/10.1177/0333102410378048
Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. Cephalalgia. 2014;34(2):126–35. DOI: https://doi.org/10.1177/0333102413500726
Banerjee M, Findley LJ. Sumatriptan in the treatment of acute migraine with aura. Cephalalgia. 1992;12(1):39–44. DOI: https://doi.org/10.1046/j.1468-2982.1992.1201039.x
Barbanti P, Carpay JA, Kwong WJ, Ahmad F, Boswell D. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin. 2004;20(12):2021–9. DOI: https://doi.org/10.1185/030079904X15200
Barbanti P, Fofi L, Dall'Armi V, Aurilia C, Egeo G, Vanacore N, et al. Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. J Headache Pain. 2012;13(5):407–14. DOI: https://doi.org/10.1007/s10194-012-0440-y
Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain. 2011;12(3):361–8. DOI: https://doi.org/10.1007/s10194-011-0325-5
Bigal ME, Lipton RB, Newman LC, Pierce MW, Silberstein SD. Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. Headache. 2015;55(8):1124–32. DOI: https://doi.org/10.1111/head.12606
Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol. 1999;42(3):173–9. DOI: https://doi.org/10.1159/000008094
Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. J Intern Med. 1993;234(2):211–6. DOI: https://doi.org/10.1111/j.1365-2796.1993.tb00732.x
Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25(9):735–42. DOI: https://doi.org/10.1111/j.1468-2982.2005.00981.x
Brandes JL, Poole A c, Kallela M, Schreiber CP, MacGregor EA, Silberstein SD, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29(11):1133–48. DOI: https://doi.org/10.1111/j.1468-2982.2009.01840.x
Bussone G, Manzoni GC, Cortelli P, Roncolato M, Fabbri L, Benassuti C. Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. Neurol Sci. 2000;21(5):272–8. DOI: https://doi.org/10.1007/s100720070064
Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology. 1993;43(7):1363–8. DOI: https://doi.org/10.1212/WNL.43.7.1363
Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20(9):1465–72. DOI: https://doi.org/10.1185/030079904X2745
Cady RK, Martin VT, Géraud G, Rodgers A, Zhang Y, Ho AP, et al. Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. Headache J Head Face Pain. 2009;49(5):687–96. DOI: https://doi.org/10.1111/j.1526-4610.2009.01412.x
Cady RK, McAllister PJ, Spierings ELH, Messina J, Carothers J, Djupesland PG, et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache. 2015;55(1):88–100. DOI: https://doi.org/10.1111/head.12472
Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. J Headache Pain. 2017;18(1):17. DOI: https://doi.org/10.1186/s10194-016-0717-7
Carpay HA, Matthijsse P, Steinbuch M, Mulder PG. Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study. Cephalalgia. 1997;17(5):591–5. DOI: https://doi.org/10.1046/j.1468-2982.1997.1705591.x
Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004;26(2):214–23. DOI: https://doi.org/10.1016/S0149-2918(04)90020-3
Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17(9):653–67. DOI: https://doi.org/10.2165/00023210-200317090-00005
Christie S, Göbel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol. 2003;49(1):20–9. DOI: https://doi.org/10.1159/000067018
Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001;23(1):127–45. DOI: https://doi.org/10.1016/S0149-2918(01)80036-9
Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73–84. DOI: https://doi.org/10.1111/j.1526-4610.2010.01799.x
Cull RE, Price WH, Dunbar A. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J Neurol Neurosurg Psychiatry. 1997;62(5):490–5. DOI: https://doi.org/10.1136/jnnp.62.5.490
Dahlöf C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being. Cephalalgia. 1992;12(4):214–20. DOI: https://doi.org/10.1046/j.1468-2982.1992.1204214.x
Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia. 2000;20(9):830–4. DOI: https://doi.org/10.1046/j.1468-2982.2000.00126.x
Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med. 1998;7(3):234–40. DOI: https://doi.org/10.1001/archfami.7.3.234
Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology. 2002;58(11):1660–5. DOI: https://doi.org/10.1212/WNL.58.11.1660
Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St. Cephalalgia. 1999;19(6):581–8; discussion 542. DOI: https://doi.org/10.1046/j.1468-2982.1999.019006581.x
Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlöf C, et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2001;21(6):672–9. DOI: https://doi.org/10.1046/j.0333-1024.2001.00222.x
Diener H-C, Jansen J-P, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol. 2002;47(2):99–107. DOI: https://doi.org/10.1159/000047960
Diener H-C. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin. 2005;21(10):1603–10. DOI: https://doi.org/10.1185/030079905X65448
Diener H-C, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache. 2005;45(7):874–82. DOI: https://doi.org/10.1111/j.1526-4610.2005.05151.x
Díez FI, Straube A, Zanchin G. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol. 2007;254(2):242–9. DOI: https://doi.org/10.1007/s00415-006-0352-3
Djupesland PG, Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia. 2010;30(8):933–42. DOI: https://doi.org/10.1177/0333102409359314
Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19(2):125–36. DOI: https://doi.org/10.2165/00023210-200519020-00003
Dowson AJ, Massiou H, Laínez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22(6):453–61. DOI: https://doi.org/10.1046/j.1468-2982.2002.00394.x
Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia. 2002;22(2):101–6. DOI: https://doi.org/10.1046/j.1468-2982.2002.00319.x
Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain. 2005;6(2):81–7. DOI: https://doi.org/10.1007/s10194-005-0156-3
Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obs Gynecol. 1995;86(6):911–6. DOI: https://doi.org/10.1016/0029-7844(95)00288-3
Färkkilä M, Olesen J, Dahlöf C, Stovner LJ, ter Bruggen JP, Rasmussen S, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23(6):463–71. DOI: https://doi.org/10.1046/j.1468-2982.2003.00554.x
Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14(5):330–8. DOI: https://doi.org/10.1046/j.1468-2982.1994.1405330.x
Freitag FG, Cady R, DiSerio F, Elkind A, Gallagher RM, Goldstein J, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache. 2001;41(4):391–8. DOI: https://doi.org/10.1046/j.1526-4610.2001.111006391.x
Freitag F, Taylor FR, Hamid MA, Rodgers A, Hustad CM, Ramsey KE, et al. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study. Headache. 2008;48(3):368–77. DOI: https://doi.org/10.1111/j.1526-4610.2007.00954.x
Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache. 2008;48(3):341–54. DOI: https://doi.org/10.1111/j.1526-4610.2007.01044.x
Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005;64(3):463–8. DOI: https://doi.org/10.1212/01.WNL.0000150904.28131.DD
Friedman BW, Hochberg M, Esses D, Bijur PE, Corbo J, Paternoster J, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache. 2006;46(6):934–41. DOI: https://doi.org/10.1111/j.1526-4610.2006.00467.x
BW F, Solorzano C, Esses D, Xia S, Hochberg M, Dua N, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. Ann Emerg Med. 2010 Jul;56(1):7–17. DOI: https://doi.org/10.1016/j.annemergmed.2010.02.005
Friedman MH, Peterson SJ, Behar CF, Zaidi Z. Intraoral chilling versus oral sumatriptan for acute migraine. Hear Dis. 2001;3(6):357–61. DOI: https://doi.org/10.1097/00132580-200111000-00003
Gallagher RM, Dennish G, Spierings EL, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache. 2000;40(2):119–28. DOI: https://doi.org/10.1046/j.1526-4610.2000.00017.x
Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia. 2003;23(9):869–76. DOI: https://doi.org/10.1046/j.1468-2982.2003.00593.x
Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia. 2000;20(1):30–8. DOI: https://doi.org/10.1046/j.1468-2982.2000.00004.x
Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol. 2002;47(2):88–98. DOI: https://doi.org/10.1159/000047959
Ghaderibarmi F, Tavakkoli N, Togha M. Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack. Acta Med Iran. 2015;53(10):633–6.
Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia. 1997;17(6):647–51. DOI: https://doi.org/10.1046/j.1468-2982.1997.1706647.x
Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338(8770):782–3. DOI: https://doi.org/10.1016/0140-6736(91)90666-D
Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology. 2000;54(1):156–63. DOI: https://doi.org/10.1212/WNL.54.1.156
Goadsby PJ, Massiou H, Pascual J, Diener H-C, Dahlöf CGH, Mateos V, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand. 2007;115(1):34–40. DOI: https://doi.org/10.1111/j.1600-0404.2006.00739.x
Göbel H, Winter P, Boswell D, Crisp A, Becker W, Hauge T, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Clin Ther. 2000 Aug;22(8):981–9. DOI: https://doi.org/10.1016/S0149-2918(00)80069-7
Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache. 1998;38(10):737–47. DOI: https://doi.org/10.1046/j.1526-4610.1998.3810737.x
Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005;45(8):973–82. DOI: https://doi.org/10.1111/j.1526-4610.2005.05177.x
Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52(9):1402–10. DOI: https://doi.org/10.1111/j.1526-4610.2012.02198.x
Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H. Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group. Headache. 1994;34(10):559–63. DOI: https://doi.org/10.1111/j.1526-4610.1994.hed3410559_a.x
Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia. 1997;17(1):31–6. DOI: https://doi.org/10.1046/j.1468-2982.1997.1701031.x
Gruffyd-Jones K, Kies B, Middleton A, Mulder LJ, Røsjø Ø, Millson DS. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. Eur J Neurol. 2001;8(3):237–45. DOI: https://doi.org/10.1046/j.1468-1331.2001.00218.x
Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther. 2000;22(8):970–80. DOI: https://doi.org/10.1016/S0149-2918(00)80068-5
Henry P, D’Allens H, French Migraine Network Bordeaux-Lyon-Grenoble. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble. Headache. 1993;33(8):432–5. DOI: https://doi.org/10.1111/j.1526-4610.1993.hed3308432.x
Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(1):99–109. DOI: https://doi.org/10.1016/j.clinthera.2007.01.012
Jelinski SE, Becker WJ, Christie SN, Ahmad FE, Pryse-Phillips W, Simpson SD. Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci. 2006;33(1):73–9. DOI: https://doi.org/10.1017/S031716710000473X
Jensen K, Tfelt-Hansen P, Hansen EW, Krøis EH, Pedersen OS. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia. 1995;15(5):423–9. DOI: https://doi.org/10.1046/j.1468-29821995.1505423.x
Kelly AM, Ardagh M, Curry C, D'Antonio J, Zebic S. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med. 1997;14(4):209–11. DOI: https://doi.org/10.1136/emj.14.4.209
Klapper J, Lucas C, Røsjø Ø, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004;24(11):918–24. DOI: https://doi.org/10.1111/j.1468-2982.2004.00735.x
Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache. 1997;37(10):640–5. DOI: https://doi.org/10.1046/j.1526-4610.1997.3710640.x
Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia. 2004;24(7):540–6. DOI: https://doi.org/10.1111/j.1468-2982.2004.00707.x
Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010;56(1):1–6. DOI: https://doi.org/10.1016/j.annemergmed.2009.11.020
Krymchantowski A V, Filho PFM, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia. 2006;26(7):871–4. DOI: https://doi.org/10.1111/j.1468-2982.2006.01136.x
Láinez MJA, Galván J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol. 2007;14(3):269–75. DOI: https://doi.org/10.1111/j.1468-1331.2006.01594.x
Lewis DW, Winner P, Hershey AD, Wasiewski WW. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120(2):390–6. DOI: https://doi.org/10.1542/peds.2007-0085
Lines CR, Vandormael K, Malbecq W. A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain. 2001;93(2):185–90. DOI: https://doi.org/10.1016/S0304-3959(01)00315-3
Lipton RB, Stewart W, Cady R, Hall C, O’quinn S, Kuhn T, et al. Sumatriptan for the Range of Headaches in Migraine Sufferers: Results of the Spectrum Study. Headache J Head Face Pain. 2000 Nov;40(10):783–91. DOI: https://doi.org/10.1046/j.1526-4610.2000.00143.x
Loder E, Brandes JL, Silberstein S, Skobieranda F, Bohidar N, Wang L, et al. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache. 2001;41(8):745–53. DOI: https://doi.org/10.1046/j.1526-4610.2001.01138.x
Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004;44(2):120–30. DOI: https://doi.org/10.1111/j.1526-4610.2004.04027.x
Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. Curr Med Res Opin. 2005;21(3):381–9. DOI: https://doi.org/10.1185/030079905X28926
Maghbooli M, Golipour F, Moghimi Esfandabadi A, Yousefi M. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytother Res. 2014;28(3):412–5. DOI: https://doi.org/10.1002/ptr.4996
Marín AC, Reyna ER, Vargas HC, Medina MJF, Arroyo JVE. Eficacia de la tetracaína intranasal en el ataque agudo de migraña vs. eletriptan por vía oral. Effic Tetracaine intranasal vs oral acute attack migraine eletriptan. 2011 Jul;44(3):81–7.
Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005;12(10):774–81. DOI: https://doi.org/10.1111/j.1468-1331.2005.01076.x
Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology. 1997;49(6):1485–90. DOI: https://doi.org/10.1212/WNL.49.6.1485
Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache J Head Face Pain. 2003;43(3):214–22. DOI: https://doi.org/10.1046/j.1526-4610.2003.03044.x
Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache. 2004;44(7):669–73. DOI: https://doi.org/10.1111/j.1526-4610.2004.04125.x
Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache J Head Face Pain. 2007;47(2):189–98. DOI: https://doi.org/10.1111/j.1526-4610.2006.00686.x
McGinley JS, Buse DC, Shulman KJ, Wirth RJ, Hugentobler E, Lipton RB. Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial. Headache. 2019 Jul;59(7):1002–13. DOI: https://doi.org/10.1111/head.13530
Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21(3):173–5. DOI: https://doi.org/10.1016/S0735-6757(02)42256-5
Miljković S, Smajlović D, Tirić Campara M, Jurina R, Duranović Vinković L, Janković SM, et al. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan;22(1):17–22.
Misra M, Sharma T, Kalra J, Goel D, Dhasmana DC. Comparative Efficacy and Tolerability of Sumatriptan, Ergotamine, Naproxen and Rizatriptan in Moderate to Severe Acute Attack of Migraine. JK Sci. 2010 Oct;12(4):175–9.
Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain. 2007;8(3):175–9. DOI: https://doi.org/10.1007/s10194-007-0386-7
Monda V Di, Nicolodi M, Aloisio A, Bianco P Del, Fonzari M, Grazioli I, et al. Efficacy of a Fixed Combination of Indomethacin, Prochlorperazine, and Caffeine Versus Sumatriptan in Acute Treatment of Multiple Migraine Attacks: A Multicenter, Randomized, Crossover Trial. Headache J Head Face Pain. 2003 Sep;43(8):835–44. DOI: https://doi.org/10.1046/j.1526-4610.2003.03161.x
Moon H-S, Chu MK, Park JW, Oh K, Chung JM, Cho YJ, et al. Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Neurol. 2010;6(1):27–32. DOI: https://doi.org/10.3988/jcn.2010.6.1.27
Moshtaghion H, Heiranizadeh N, Rahimdel A, Esmaeili A, Hashemian H, Hekmatimoghaddam S. The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial. Pain Pr. 2015;15(8):701–5. DOI: https://doi.org/10.1111/papr.12230
Müller T, Lohse L. Efficacy of parecoxib, sumatriptan, and rizatriptan in the treatment of acute migraine attacks. Clin Neuropharmacol. 2011;34(6):206–9. DOI: https://doi.org/10.1097/WNF.0b013e31823429cd
Myllylä V V, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache. 1998;38(3):201–7. DOI: https://doi.org/10.1046/j.1526-4610.1998.3803201.x
Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994;241(3):138–44. DOI: https://doi.org/10.1007/BF00868340
Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obs Gynecol. 2003;102(4):835–42. DOI: https://doi.org/10.1097/00006250-200310000-00027
Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41(3):248–56. DOI: https://doi.org/10.1046/j.1526-4610.2001.111006248.x
A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. Eur Neurol. 1991;31(5):332–8. DOI: https://doi.org/10.1159/000116761
Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325(5):316–21. DOI: https://doi.org/10.1056/NEJM199108013250504
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol. 1991;31(5):314–22. DOI: https://doi.org/10.1159/000116759
Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia. 2000;20(5):455–61. DOI: https://doi.org/10.1046/j.1468-2982.2000.00069.x
Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20(6):588–96. DOI: https://doi.org/10.1046/j.1468-2982.2000.00091.x
Pascual J, Bussone G, Hernandez JF, Allen C, Vrijens F, Patel K. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. Eur Neurol. 2001;45(4):275–83. DOI: https://doi.org/10.1159/000052143
Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F. High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. J Int Med Res. 1995;23(2):96–105. DOI: https://doi.org/10.1177/030006059502300202
Pini LA, Guerzoni S, Cainazzo M, Ciccarese M, Prudenzano MP, Livrea P. Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. J Headache Pain. 2012;13(8):669–75. DOI: https://doi.org/10.1007/s10194-012-0484-z
Rahimdel A, Mellat A, Zeinali A, Jafari E, Ayatollahi P. Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial. Iran J Med Sci. 2014;39(2 Suppl):171–7.
Rao AS, Gelaye B, Kurth T, Dash PD, Nitchie H, Peterlin BL. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. Headache. 2016;56(2):331–40. DOI: https://doi.org/10.1111/head.12767
Rapoport AM, Visser WH, Cutler NR, Alderton CJ, Paulsgrove LA, Davis RL, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology. 1995;45(8):1505–9. DOI: https://doi.org/10.1212/WNL.45.8.1505
Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49(5):1210–8. DOI: https://doi.org/10.1212/WNL.49.5.1210
Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46(1):101–9. DOI: https://doi.org/10.1111/j.1526-4610.2006.00313.x
Russell MB, Holm-Thomsen OE, Rishøj Nielsen M, Cleal A, Pilgrim AJ, Olesen J. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia. 1994;14(4):291–6. DOI: https://doi.org/10.1046/j.1468-2982.1994.1404291.x
Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002;59(8):1210–7. DOI: https://doi.org/10.1212/WNL.59.8.1210
Sandrini G, Cerbo R, Del Bene E, Ferrari A, Genco S, Grazioli I, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu. Int J Clin Pr. 2007;61(8):1256–69. DOI: https://doi.org/10.1111/j.1742-1241.2007.01458.x
Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia. 2004;24(7):596–602. DOI: https://doi.org/10.1111/j.1468-2982.2004.00723.x
Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia. 1997;17(8):867–72; discussion 800. DOI: https://doi.org/10.1046/j.1468-2982.1997.1708867.x
Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain. 2011;12(2):219–26. DOI: https://doi.org/10.1007/s10194-010-0243-y
Savi L, Mogavero S, Egan CG. Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. Drug Des Devel Ther. 2014;8:983–92. DOI: https://doi.org/10.2147/DDDT.S61295
Schulman EA. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. Headache. 2012;52(2):204–12. DOI: https://doi.org/10.1111/j.1526-4610.2011.02065.x
Scott RJ, Aitchison WR, Barker PR, McLaren GI. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. QJM. 1996;89(8):613–22. DOI: https://doi.org/10.1093/qjmed/89.8.613
Seeburger JL, Taylor FR, Friedman D, Newman L, Ge Y, Zhang Y, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011;31(7):786–96. DOI: https://doi.org/10.1177/0333102410390399
Seeburger JL, Cady RK, Winner P, MacGregor A, Valade D, Ge Y, et al. Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. Headache. 2012;52(1):57–67. DOI: https://doi.org/10.1111/j.1526-4610.2011.02027.x
Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache. 2003;43(3):202–13. DOI: https://doi.org/10.1046/j.1526-4610.2003.03043.x
Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obs Gynecol. 2000;96(2):237–42. DOI: https://doi.org/10.1097/00006250-200008000-00016
Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63(2):261–9. DOI: https://doi.org/10.1212/01.WNL.0000134620.30129.D6
Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45(8):983–91. DOI: https://doi.org/10.1111/j.1526-4610.2005.05178.x
Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997;49(5):1219–25. DOI: https://doi.org/10.1212/WNL.49.5.1219
Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001;58(6):944–50. DOI: https://doi.org/10.1001/archneur.58.6.944
Spierings ELH, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs. 2004;18(15):1133–41. DOI: https://doi.org/10.2165/00023210-200418150-00007
Spierings ELH, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med. 2009;10(4):633–8. DOI: https://doi.org/10.1111/j.1526-4637.2009.00618.x
Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000;40(7):513–20. DOI: https://doi.org/10.1046/j.1526-4610.2000.00082.x
Stark R, Dahlöf C, Haughie S, Hettiarachchi J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia. 2002;22(1):23–32. DOI: https://doi.org/10.1046/j.1468-2982.2002.00300.x
Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia. 2003;23(10):942–52. DOI: https://doi.org/10.1046/j.1468-2982.2003.00617.x
Talabi S, Masoumi B, Azizkhani R, Esmailian M. Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial. J Res Med Sci. 2013;18(8):695–8.
Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998;38(4):281–7. DOI: https://doi.org/10.1046/j.1526-4610.1998.3804281.x
Tepper SJ, Donnan GA, Dowson AJ, Bomhof MA, Elkind A, Meloche J, et al. A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin. 1999;15(4):254–71. DOI: https://doi.org/10.1185/03007999909116496
Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, et al. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Headache. 2006;46(1):115–24. DOI: https://doi.org/10.1111/j.1526-4610.2006.00300.x
Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995;346(8980):923–6. DOI: https://doi.org/10.1016/S0140-6736(95)91554-0
Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache. 1998;38(10):748–55. DOI: https://doi.org/10.1046/j.1526-4610.1998.3810748.x
Tfelt-Hansen P, Bach FW, Daugaard D, Tsiropoulos I, Riddersholm B. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. J Headache Pain. 2006;7(6):389–94. DOI: https://doi.org/10.1007/s10194-006-0333-z
A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. Eur Neurol. 1992;32(3):177–84. DOI: https://doi.org/10.1159/000116818
Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. Eur Neurol. 1991;31(5):306–13. DOI: https://doi.org/10.1159/000116758
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. Eur Neurol. 1991;31(5):323–31. DOI: https://doi.org/10.1159/000116760
Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bès A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996;47(2):361–5. DOI: https://doi.org/10.1212/WNL.47.2.361
Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20(12):1019–26. DOI: https://doi.org/10.2165/00023210-200620120-00005
Tullo V, Allais G, Ferrari MD, Curone M, Mea E, Omboni S, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci. 2010;31 Suppl 1:S51-4. DOI: https://doi.org/10.1007/s10072-010-0273-x
Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia. 1992;12(5):308–13. DOI: https://doi.org/10.1046/j.1468-2982.1992.1205308.x
Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol. 1996;53(11):1132–7. DOI: https://doi.org/10.1001/archneur.1996.00550110072014
Wang S-J, Fuh J-L, Wu Z-A. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc. 2007;70(2):39–46. DOI: https://doi.org/10.1016/S1726-4901(09)70300-4
Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics. 2000;18(6):557–66. DOI: https://doi.org/10.2165/00019053-200018060-00003
Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006;28(4):517–26. DOI: https://doi.org/10.1016/j.clinthera.2006.03.013
Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53(2):180–4. DOI: https://doi.org/10.1001/archneur.1996.00550020092020
Zhang A, Jiang T, Luo Y, Zheng Z, Shi X, Xiao Z, et al. Efficacy of intravenous propacetamol hydrochloride in the treatment of an acute attack of migraine. Eur J Intern Med. 2014;25(7):629–32. DOI: https://doi.org/10.1016/j.ejim.2014.06.007
Rücker G. netmeta: Network Meta-Analysis using Frequentist Methods version 1.3-0 from CRAN. 2021.
Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Cham: Springer International Publishing; 2015. (Use R!). DOI: https://doi.org/10.1007/978-3-319-21416-0
Kötter T, da Costa BR, Fässler M, Blozik E, Linde K, Jüni P, et al. Metamizole-Associated Adverse Events: A Systematic Review and Meta-Analysis. Manzoli L, editor. PLoS One. 2015 Apr 13;10(4):1–18. DOI: https://doi.org/10.1371/journal.pone.0122918
Hamerschlak N, Maluf E, Biasi Cavalcanti A, Avezum Á, Eluf-Neto J, Passeto Falcão R, et al. Incidence and risk factors for agranulocytosis in Latin American countries - The Latin Study: A multicenter study. Eur J Clin Pharmacol. 2008 Sep;64(9):921–9. DOI: https://doi.org/10.1007/s00228-008-0513-7
Dal Pizzol T da S, Fontanella AT, Cardoso Ferreira MB, Bertoldi AD, Borges RB, Mengue SS. Analgesic use among the Brazilian population: Results from the national survey on access, use and promotion of rational use of medicines (PNAUM). PLoS One. 2019 Mar 1;14(3). DOI: https://doi.org/10.1371/journal.pone.0214329
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mario Fernando Prieto Peres, Wanessa Alessandra Ruiz Scala, Ricardo Salazar
This work is licensed under a Creative Commons Attribution 4.0 International License.
